Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Achillion Pharmaceuticals in a research report issued to clients and investors on Monday. Leerink Swann analyst J. Schwartz forecasts that the biopharmaceutical company will earn ($0.16) per share for the quarter. Leerink Swann currently has a “Buy” rating and a $5.00 target price on the stock. Leerink Swann also issued estimates for Achillion Pharmaceuticals’ Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.17) EPS and Q4 2018 earnings at ($0.18) EPS.

A number of other equities research analysts also recently issued reports on the company. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Monday, November 13th. Chardan Capital reaffirmed a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Ladenburg Thalmann Financial Services decreased their price objective on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Robert W. Baird reissued a “neutral” rating and set a $4.00 target price (down previously from $5.00) on shares of Achillion Pharmaceuticals in a research report on Tuesday, September 12th. Finally, ValuEngine downgraded Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, September 11th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $5.13.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at $2.86 on Tuesday. Achillion Pharmaceuticals has a twelve month low of $2.85 and a twelve month high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. During the same period in the previous year, the business posted ($0.15) EPS.

Institutional investors and hedge funds have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. lifted its position in Achillion Pharmaceuticals by 3.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 800 shares in the last quarter. SG Americas Securities LLC raised its position in Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 4,144 shares during the period. Legal & General Group Plc raised its position in Achillion Pharmaceuticals by 53.8% in the second quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 15,000 shares during the period. Voya Investment Management LLC raised its position in Achillion Pharmaceuticals by 13.7% in the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 6,730 shares during the period. Finally, Bank of Montreal Can raised its position in Achillion Pharmaceuticals by 6.4% in the second quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 3,410 shares during the period. 76.93% of the stock is currently owned by institutional investors.

In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a document filed with the SEC, which is available through this link. 7.24% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Expected to Earn Q1 2018 Earnings of ($0.16) Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/12/achillion-pharmaceuticals-inc-achn-expected-to-earn-q1-2018-earnings-of-0-16-per-share.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.